Skip to content

Click here to learn more about World Vaccine Congress West Coast, 27-30 Nov 2023.

  • RESOURCES:      
  • For Patients/Caregivers
  • For Medical Providers
  • For Researchers
solve-me-logo-color
Join Solve Together
Donate
  • ME/CFS + Long Covid
      • What is ME/CFS?
      • What is Long Covid?
      • Quiz: Do I Have ME/CFS?
      • Quiz: Do I Have Long Covid?
      • Solve Long Covid
      • Long Haul Voices
      • Patient/Caregiver Resources
      • Medical Provider Resources
  • Research
      • Solve Together
      • Ramsay Research Grants
      • Meet the Researchers
      • Applying for a Grant
  • Advocacy
      • Annual Advocacy Events
      • Take Action Now
      • EmPOWER M.E.
      • Advocacy Cafe Chats
      • Tools + Resources
      • LC-PLAN
      • Statements + Letters
      • Humans of Chronic Illness
  • Donate + Engage
      • Get Involved
      • How Long Until We Solve Long Covid?
      • Donate Today
      • Other Ways To Give
  • News + Insights
      • Research 1st
      • The Chronicle
      • Press Releases
      • Alerts + Blog Posts
      • Media Kit + Solve M.E. in the News
      • Webinars
      • Events
      • Subscribe to Our Newsletter
  • About Us
      • Our Board
      • Our Staff
      • Our Research Advisory Council (RAC)
      • Lived Experience Taskforce (LET)
      • Our Partners
      • Solve M.E. Financials
      • Contact Us
      • Join Our Team

Learn more about full-time, contractual, and consultant roles with Solve here.

solve-me-logo-color

Day: February 8, 2021

Solve M.E. President Oved Amitay joins World Health Organization seminar on Long Covid

Solve M.E. President and CEO Oved Amitay will join other experts as a participant in a series of seminars presented by the World Health Organization (WHO) designed to improve our […]

solve-me-logo-ko
thumbnail_Solve_Long_Covid_Initiative_logo_white

Making Breakthroughs Possible

Facebook Twitter Instagram Youtube Linkedin

Solve ME/CFS Initiative

350 N Glendale Ave.
Suite B #368
Glendale, CA 91206

SolveCFS@SolveCFS.org
704-364-0016

Explore

About Solve M.E.
Solve Long Covid NOW
Long Covid Initiative
What is ME/CFS?
What is Long Covid?
Advocacy Center
Solve Together
Research Grants

Donate

Ways to Give
Monthly Giving
Gifts of Securities
Donate

Join our newsletter

Subscribe

Copyright © 2022 The Solve ME/CFS Initiative. All rights reserved.

Privacy Policy
Terms of Use
Accessibility Statement
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT

Help us keep you updated.

Please let us know more about you.

 

Covid Survey
Which best describes you?
I’d like more information on:
What efforts are you taking to help stop the long haul?

Help us keep you updated.

Please let us know more about you.

 

Covid Survey
Which best describes you?
I’d like more information on:
What efforts are you taking to help stop the long haul?

Indiana

Cumulative Cost to Jan 31, 2022: $8.7B
% of Population with Long Covid: 7.3%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 481,100
# of Individuals with Disabling Long Covid: 160,000

Illinois

Cumulative Cost to Jan 31, 2022: $16B
% of Population with Long Covid: 10%
% of Population with Disabling Long Covid: 4%
# of Individuals with Long Covid: 860,000
# of Individuals with Disabling Long Covid: 285,000

Idaho

Cumulative Cost to Jan 31, 2022: $2B
% of Population with Long Covid: 6.7%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 113,000
# of Individuals with Disabling Long Covid: 37,500

Hawaii

Cumulative Cost to Jan 31, 2022: $1.1B
% of Population with Long Covid: 4.4%
% of Population with Disabling Long Covid: 1.4%
# of Individuals with Long Covid: 62,000
# of Individuals with Disabling Long Covid: 20,500

Georgia

Cumulative Cost to Jan 31, 2022: $12.6B
% of Population with Long Covid: 6.8%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 702,000
# of Individuals with Disabling Long Covid: 233,000

Florida

Cumulative Cost to Jan 31, 2022: $30B
% of Population with Long Covid: 7.9%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 1,640,000
# of Individuals with Disabling Long Covid: 544,000

Delaware

Cumulative Cost to Jan 31, 2022: $1.3B
% of Population with Long Covid: 7.7%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 73,000
# of Individuals with Disabling Long Covid: 24,000

Connecticut

Cumulative Cost to Jan 31, 2022: $3.7B
% of Population with Long Covid: 5.7%
% of Population with Disabling Long Covid: 1.9%
# of Individuals with Long Covid: 205,000
# of Individuals with Disabling Long Covid: 68,000

Colorado

Cumulative Cost to Jan 31, 2022: $6.7B
% of Population with Long Covid: 6.7%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 370,00
# of Individuals with Disabling Long Covid: 123,000

California

Cumulative Cost to Jan 31, 2022: $43B
% of Population with Long Covid: 6.3%
% of Population with Disabling Long Covid: 2.1%
# of Individuals with Long Covid: 2,470,000
# of Individuals with Disabling Long Covid: 817,000

Arkansas

Cumulative Cost to Jan 31, 2022: $4.1B
% of Population with Long Covid: 7.7%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 230,000
# of Individuals with Disabling Long Covid: 76,500

Arizona

Cumulative Cost to Jan 31, 2022: $9.8B
% of Population with Long Covid: 8%
% of Population with Disabling Long Covid: 2.7%
# of Individuals with Long Covid: 554,000
# of Individuals with Disabling Long Covid: 184,000

Alaska

Cumulative Cost to Jan 31, 2022: $1B
% of Population with Long Covid: 8.4%
% of Population with Disabling Long Covid: 2.8%
# of Individuals with Long Covid: 62,000
# of Individuals with Disabling Long Covid: 21,000

Oregon

Cumulative Cost to Jan 31, 2022: $3.3B
% of Population with Long Covid: 4.6%
% of Population with Disabling Long Covid: 1.5%
# of Individuals with Long Covid: 187,000
# of Individuals with Disabling Long Covid: 62,000

Alabama

Cumulative Cost to Jan 31, 2022: $6.5B
% of Population with Long Covid: 7.5%
% of Population with Disabling Long Covid: 2.5%
# of Individuals with Long Covid: 363,000
# of Individuals with Disabling Long Covid: 121,000

Washington

Cumulative Cost to Jan 31, 2022: $6.7B
% of Population with Long Covid: 5.4%
% of Population with Disabling Long Covid: 1.8%
# of Individuals with Long Covid: 394,000
# of Individuals with Disabling Long Covid: 130,000

Wyoming

Cumulative Cost to Jan 31, 2022: $775M
% of Population with Long Covid: 7.5%
% of Population with Disabling Long Covid: 2.5%
# of Individuals with Long Covid: 43,500
# of Individuals with Disabling Long Covid: 14,500

Wisconsin

Cumulative Cost to Jan 31, 2022: $8.1B
% of Population with Long Covid: 7.8%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 450,000
# of Individuals with Disabling Long Covid: 150,000

West Virginia

Cumulative Cost to Jan 31, 2022: $2.3B
% of Population with Long Covid: 7.2%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 132,000
# of Individuals with Disabling Long Covid: 44,000

Virginia

Cumulative Cost to Jan 31, 2022: $8.2B
% of Population with Long Covid: 5.4%
% of Population with Disabling Long Covid: 1.8%
# of Individuals with Long Covid: 457,000
# of Individuals with Disabling Long Covid: 151,000

Vermont

Cumulative Cost to Jan 31, 2022: $500M
% of Population with Long Covid: 4.5%
% of Population with Disabling Long Covid: 1.5%
# of Individuals with Long Covid: 28,000
# of Individuals with Disabling Long Covid: 9,000

Utah

Cumulative Cost to Jan 31, 2022: $4.7B
% of Population with Long Covid: 10%
% of Population with Disabling Long Covid: 4%
# of Individuals with Long Covid: 262,000
# of Individuals with Disabling Long Covid: 87,000

Texas

Cumulative Cost to Jan 31, 2022: $33B
% of Population with Long Covid: 6.6%
% of Population with Disabling Long Covid: 2%
# of Individuals with Long Covid: 1,840,000
# of Individuals with Disabling Long Covid: 611,000

Tennessee

Cumulative Cost to Jan 31, 2022: $9.9B
% of Population with Long Covid: 8.3%
% of Population with Disabling Long Covid: 2.8%
# of Individuals with Long Covid: 555,000
# of Individuals with Disabling Long Covid: 184,000

South Dakota

Cumulative Cost to Jan 31, 2022: $1.2B
% of Population with Long Covid: 7.8%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 67,000
# of Individuals with Disabling Long Covid: 22,100

South Carolina

Cumulative Cost to Jan 31, 2022: $7.2B
% of Population with Long Covid: 8.3%
% of Population with Disabling Long Covid: 2.7%
# of Individuals with Long Covid: 410,000
# of Individuals with Disabling Long Covid: 136,000

Rhode Island

Cumulative Cost to Jan 31, 2022: $1.8B
% of Population with Long Covid: 9.5%
% of Population with Disabling Long Covid: 3.1%
# of Individuals with Long Covid: 100,000
# of Individuals with Disabling Long Covid: 33,000

Pennsylvania

Cumulative Cost to Jan 31, 2022: $14B
% of Population with Long Covid: 6.1%
% of Population with Disabling Long Covid: 2%
# of Individuals with Long Covid: 783,000
# of Individuals with Disabling Long Covid: 260,000

Oklahoma

Cumulative Cost to Jan 31, 2022: $5.1B
% of Population with Long Covid: 7.4%
% of Population with Disabling Long Covid: 2.5%
# of Individuals with Long Covid: 290,000
# of Individuals with Disabling Long Covid: 96,000

Ohio

Cumulative Cost to Jan 31, 2022: $14B
% of Population with Long Covid: 6.6%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 763,000
# of Individuals with Disabling Long Covid: 253,000

North Dakota

Cumulative Cost to Jan 31, 2022: $1.2B
% of Population with Long Covid: 8.8%
% of Population with Disabling Long Covid: 2.9%
# of Individuals with Long Covid: 66,500
# of Individuals with Disabling Long Covid: 22,000

North Carolina

Cumulative Cost to Jan 31, 2022: $12.6B
% of Population with Long Covid: 7.1%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 716,000
# of Individuals with Disabling Long Covid: 238,000

New York

Cumulative Cost to Jan 31, 2022: $17.5B
% of Population with Long Covid: 7.2%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 1,400,000
# of Individuals with Disabling Long Covid: 464,000

New Mexico

Cumulative Cost to Jan 31, 2022: $2.5B
% of Population with Long Covid: 6.8%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 142,000
# of Individuals with Disabling Long Covid: 47,000

New Jersey

Cumulative Cost to Jan 31, 2022: $11B
% of Population with Long Covid: 7%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 619,000
# of Individuals with Disabling Long Covid: 205,000

New Hampshire

Cumulative Cost to Jan 31, 2022: $1.5B
% of Population with Long Covid: 6.1%
% of Population with Disabling Long Covid: 2%
# of Individuals with Long Covid: 81,500
# of Individuals with Disabling Long Covid: 27,000

Nevada

Cumulative Cost to Jan 31, 2022: $3.5B
% of Population with Long Covid: 6.7%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 195,000
# of Individuals with Disabling Long Covid: 65,000

Nebraska

Cumulative Cost to Jan 31, 2022: $2.4B
% of Population with Long Covid: 6.9%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 131,000
# of Individuals with Disabling Long Covid: 43,500

Montana

Cumulative Cost to Jan 31, 2022: $1.3B
% of Population with Long Covid: 6.9%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 72,000
# of Individuals with Disabling Long Covid: 24,000

Missouri

Cumulative Cost to Jan 31, 2022: $7.1B
% of Population with Long Covid: 6.5%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 394,000
# of Individuals with Disabling Long Covid: 131,000

Mississippi

Cumulative Cost to Jan 31, 2022: $3.9B
% of Population with Long Covid: 7.2%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 216,000
# of Individuals with Disabling Long Covid: 72,000

Minnesota

Cumulative Cost to Jan 31, 2022: $7B
% of Population with Long Covid: 7.1%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 391,000
# of Individuals with Disabling Long Covid: 130,000

Michigan

Cumulative Cost to Jan 31, 2022: $12B
% of Population with Long Covid: 6.7%
% of Population with Disabling Long Covid: 2.2%
# of Individuals with Long Covid: 669,000
# of Individuals with Disabling Long Covid: 222,000

Massachusetts

Cumulative Cost to Jan 31, 2022: $8.6B
% of Population with Long Covid: 6.9%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 472,000
# of Individuals with Disabling Long Covid: 156,000

Maryland

Cumulative Cost to Jan 31, 2022: $5.2B
% of Population with Long Covid: 4.7%
% of Population with Disabling Long Covid: 1.6%
# of Individuals with Long Covid: 281,000
# of Individuals with Disabling Long Covid: 93,000

Maine

Cumulative Cost to Jan 31, 2022: $940M
% of Population with Long Covid: 3.9%
% of Population with Disabling Long Covid: 1.3%
# of Individuals with Long Covid: 52,000
# of Individuals with Disabling Long Covid: 17,000

Louisiana

Cumulative Cost to Jan 31, 2022: $5.9B
% of Population with Long Covid: 7.1%
% of Population with Disabling Long Covid: 2.4%
# of Individuals with Long Covid: 330,000
# of Individuals with Disabling Long Covid: 110,000

Kentucky

Cumulative Cost to Jan 31, 2022: $6.1B
% of Population with Long Covid: 7.8%
% of Population with Disabling Long Covid: 2.6%
# of Individuals with Long Covid: 344,000
# of Individuals with Disabling Long Covid: 114,000

Kansas

Cumulative Cost to Jan 31, 2022: $3.9B
% of Population with Long Covid: 7.4%
% of Population with Disabling Long Covid: 2.5%
# of Individuals with Long Covid: 216,000
# of Individuals with Disabling Long Covid: 72,000

Iowa

Cumulative Cost to Jan 31, 2022: $3.9B
% of Population with Long Covid: 6.8%
% of Population with Disabling Long Covid: 2.3%
# of Individuals with Long Covid: 214,000
# of Individuals with Disabling Long Covid: 71,000

Washington D.C.

Cumulative Cost to Jan 31, 2022: $700M
% of Population with Long Covid: 5.6%
% of Population with Disabling Long Covid: 1.9%
# of Individuals with Long Covid: 38,000
# of Individuals with Disabling Long Covid: 13,000

Help us keep you updated.​..

Please let us know more about you.

 

Covid Survey
Which best describes you?
I’d like more information on:
What efforts are you taking to help stop the long haul?
  • for patients / caregivers
  • for medical providers
  • for researchers
Donate
Join Solve Together
  • ME/CFS + Long Covid
    • What is ME/CFS?
    • What is Long Covid?
    • Do I Have ME/CFS? Quiz
    • Do I Have Long Covid? Quiz
    • Solve Long Covid
    • Long Haul Voices
    • Patient and Caregiver Resources
    • Medical Providers Resources
  • Research
    • Solve Together
    • Ramsay Research Grants
    • Meet the Researchers
    • Applying for a Grant
  • Advocacy
    • Annual Advocacy Events
    • Take Action Now
    • EmPOWER M.E.
    • Advocacy Cafe Chats
    • Tools & Resources
    • LC-PLAN
    • Statements & Letters
    • Humans of Chronic Illness
  • Donate + Engage
    • Get Involved
    • How Long Until We Solve Long Covid?
    • Donate Today
    • Other Ways to Give
  • News + Insights
    • Research 1st
    • The Chronicle
    • Press Releases
    • Alerts + Blog Posts
    • Media Kit + Solve M.E. in the News
    • Webinars
    • Events
    • Subscribe to Our Newsletter
  • About Us
    • Board of Directors
    • Solve M.E. Staff
    • Research Advisory Council
    • Lived Experience Taskforce (LET)
    • Solve M.E. Partners
    • Solve M.E. Financials
    • Contact Us
    • Join Our Team

Fighting for you.

"*" indicates required fields

Make a Donation

Make a gift today and turn research into reality.

DONATE
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset